Our business strategy is focused on maintaining and continuing to develop our novel and proprietary in-silico drug Discovery Engine and on the application of the platform to the discovery of innovative preclinical drugs with the potential to address areas of significant unmet clinical and commercial need.
Decreasing cost – increasing speed
Traditional pharmaceutical and biotechnology companies are looking to decrease the cost and increase the speed and productivity of their drug discovery activities. Our in-silico drug Discovery Engine is targeted at helping them achieve this goal and we therefore anticipate significant interest as we illustrate the effectiveness of our novel approach.
Innovating with informatics
A new generation of informatics-based companies are looking at ways to use technology to redesign and “disrupt” the traditional drug discovery process. In addition to pharmaceutical and biotechnology companies, we are also targeting these companies because we believe our computational platform will be seen by them as an important innovation in this space.
New and better drugs
We also use our highly productive drug Discovery Engine to develop internal, preclinical drug discovery programmes for industrial partners looking to acquire or in-license such assets. This approach should generate revenues in the form of upfront payments, progress based milestone payments and ultimately royalties on sales.
Focus on partnerships
Our business development focus is to demonstrate the value and utility of our approach to potential partners. Because of our novel methodology, we believe there is potential to enter into several different types of collaborative partnerships and agreements in biotech, pharma and informatics to create sustainable mutual value.
What we do
Accelerating drug discovery with a novel view of disease networks
By combining biological expertise and a powerful computer-based platform, we create and analyse network models of disease to identify likely proteins that could effectively be disrupted to treat the disease.
Using our computer platform, we use the latest mathematical and data analysis techniques to augment and interrogate the vast amount of biological information currently available in both public and private databases.
We believe that our approach more realistically reflects the true complexity of disease, with its multiple and often interconnected cellular pathways. By modelling and analysing disease networks and considering the pattern of connections between proteins, and not just single pathways, we more efficiently select the very best drug-like compounds for screening and for subsequent medicinal chemistry and pre-clinical testing.
Shortening discovery time and reducing costs
With our novel methodology, significant numbers of active molecules can be identified and tested quickly. This gives benefits in terms of both cost and time.
We review our database of many millions of compounds looking for those that have the specific features necessary to disrupt the disease. As this process occurs ‘in silico’ using advanced modelling techniques, we can interrogate all the available data and identify the best compounds that match the optimal profile.
As this part of the discovery process is performed by powerful computers it is both faster, less expensive than traditional approaches, and can explore avenues not currently feasible with experimental techniques.
Creating new and better drugs
By addressing this complexity of disease, we aim to discover more efficacious drugs more effectively. By using more biologically realistic, cell and tissue-based assays we can choose and design compounds that are more likely to translate into better, more clinically efficacious drugs.
Our approach is highly productive and consistently generates hits that have been progressed into potent, selective and novel drug molecules.
The approach we adopt and the compounds we discover assist companies who want to speed up their own discovery activities, reducing their investment of time and money and ultimately advancing public health by bringing effective drugs to market more quickly.
To view information on our approach, please click here
To view information on The Drug Discovery Engine, please click here
To view information on Our Assets, please click here
To view information on the Network Biology, please click here
Dr. Raymond Barlow
Chief Executive Officer
Ray was announced as e-Therapeutics’ Chief Executive Officer in January 2017, taking up the role on 6 April 2017. Ray brings to e-Therapeutics broad experience of drug discovery, development and commercialisation, acquired through regional and global roles in the biotechnology and pharmaceutical sectors.
Having completed a BSc (Hons) in Chemistry from Leeds University in 1990, Ray moved to the University of Manchester from where he gained a PhD in Chemistry in 1994. He then spent a year at McGill University, Montreal, Canada as a post-doctoral fellow before entering the pharmaceutical industry as a Senior Scientist with Zeneca in Pharmaceutical R&D’s Technology Access and Strategic Alliances team, of which he later became Team Leader in 1998.
Following the merger with Astra, he became a Global Manager in the Discovery and Development function, in-licensing technologies and working on the development of a range of molecules, including those in oncology, cardiovascular, respiratory and inflammatory disease areas. During this period he graduated from Manchester Business School with an MBA (with distinction) and moved into the Business Development function, first as a Senior Business Analyst before his appointment as Director of Corporate Development, reporting into AstraZeneca’s London HQ. In this role he was involved in a number of transactions and was part of the team responsible for shaping AZ’s strategy with the Board, including its move into biologics. In 2004, he stepped into a Regional commercial leadership role in Brussels covering 14 countries in Central and Eastern Europe and Russia.
After 10 years with AstraZeneca, Ray moved into the biotech sector working in senior business development roles for Microscience Limited and Emergent Solutions Inc. (EBS). During this period Ray out-licensed a portfolio of Meningitis B assets to Sanofi and was involved with the team that successfully listed EBS on NASDAQ. Ray then spent five years running his own business (BD Solutions Limited) focused upon advising and aiding clients on corporate development and commercialisation projects. During this period he was CEO of Asterion Ltd, and delivered deals with Genzyme Inc. and Ipsen.
In 2010, he joined Crucell NV and was instrumental in the sale to Johnson & Johnson for whom he worked on a wide range of infectious disease and vaccine deals, before joining Amgen in 2012. In his role as Executive Director of Corporate Development at Amgen he has completed numerous deals including immuno-oncology deals with Boehringer Ingelheim and Genenta, international commercial deals with GSK and Mitsubishi Tanabe as well as playing a key part in the acquisition of Onyx Pharmaceuticals Inc. and Dezima Pharma BV.
Non - Executive Chairman
Iain Ross has over 35 years’ experience in the international life sciences and technology sectors where he has completed multiple financing transactions, and >25 years in cross-border management as a Chairman and CEO. He has led and participated in 5 Initial Public Offerings, and has direct experience of M&A transactions in Europe, USA and Pacific Rim.
Currently he is Chairman of Redx Pharma plc (AIM) and Biomer Technology Limited; and also a Non-Executive Director of Premier Veterinary Group plc (LSE); Anatara LifeSciences Ltd (ASX), and Novogen Ltd (ASX & NASDAQ). He is a qualified Chartered Director, and Vice Chairman of the Council of Royal Holloway, London University.
Previously, he has held significant roles in multi-national companies including Sandoz, Hoffman La Roche, Reed Business Publishing and Celltech Group plc where as Chief Executive Officer of Celltech Biologics plc, he moved the company from a loss-making position to reporting a net profit before the sale to Lonza. He has advised banks and private equity groups on numerous company turnarounds. These include as CEO of Quadrant Healthcare taking the Company public, signing numerous collaborations before selling the business to Elan in 2001. As Chairman and Chief Executive Officer, at Allergy Therapeutics, he re-structured the Company Balance Sheet to position Allergy Therapeutics as a virtually debt free cash generative company prior to its subsequent IPO. As Executive Chairman at Silence Therapeutics Plc (formerly SR Pharma plc), he turned the business around through M&A and established collaborations with Pfizer, Astra Zeneca and Dainippon Sumitomo before completing a merger with Intradigm Inc. Iain was appointed to the Board of e-Therapeutics in January 2016. He continues to consult for private equity groups on biotech & technology company turnarounds.
Steve joined e-Therapeutics’ management team in April 2014, having previously advised the Company in its £40 million fundraising in 2013. He is a Chartered Accountant. Prior to joining e-Therapeutics, Steve worked in the UK equity market for over 20 years. During this time he was involved primarily in research and advised on numerous flotations, acquisitions and corporate transactions. He has held various research and executive roles within UK capital market companies including Altium Capital, N+1 Singer and Peel Hunt. He co-founded Blueprint Advisors in 2012.
Brad has over 20 years’ commercial experience in the pharmaceutical and biotechnology industries gained through financial and general management roles in the UK and US.
Brad is Director and co-founder of Seven Hills Venture Partners Limited, a life sciences advisory firm based in Edinburgh. Previously Brad was Chief Financial Officer of Plethora Solutions Holdings plc, an AIM-listed speciality pharmaceutical company; Chief Executive Officer of Xcellsyz Limited, a UK venture capital-backed life science company; and Senior Director of Geron Corporation’s stem cell-focused UK subsidiary. Prior to co-founding Seven Hills, Brad was Chief Financial Officer at Cyclacel Limited, a UK oncology company, and he held senior financial management positions at ChiRex Inc., a US-based pharmaceutical CMO. Brad is a Chartered Management Accountant. He was appointed as a Non-Executive Director of e-Therapeutics in September 2008, and chairs the audit committee and the remuneration committee.
Professor Trevor Jones CBE
Trevor has over 40 years’ distinguished experience in the pharmaceutical and biotech industry as well as in academia. He is currently Chairman of the international CRO, Simbec-Orion Group Limited, and a Non-Executive Director of the Welsh investment company, Arthurian Life Sciences Limited and the global health and life sciences investment company, Perceptive Bioscience Investments Ltd. He is also Visiting Professor at King’s College, London and holds honorary degrees and Gold Medals from seven universities.
Previously, Trevor held significant roles in industry including Director of Allergan Inc from 2005 to 2015 and R&D Director of The Wellcome Foundation from 1987-1994, where he was responsible for the development of AZT, Zovirax, Lamictal, Malarone and other medicines.
Trevor has also held a number of advisory and regulatory roles including Director General of the Association of the British Pharmaceutical Industry (ABPI), board member of the European Federation of Pharmaceutical Industry Associations (EFPIA) and the International Federation of Pharmaceutical Manufacturers Associations (IFPMA), a member of the UK Government regulatory agency, The Medicines Commission, a member of the UK Government Pharmaceutical Industry Ministerial Strategy Working Group on Pharmaceuticals, an adviser to the Cabinet Office on the Human Genome Project, a member of the Prime Minister’s Task Force on the Competitiveness of the Pharmaceutical Industry (PICTF) and Chair of the Government Advisory Group on Genetics Research. He joined the e-Therapeutics board in October 2015.
Oxford Office and Registered Office
17 Blenheim Office Park
11 Waterloo Square
Newcastle Upon Tyne
Phone & Fax
Tel: +44 (0) 1993 880000
Fax: +44 (0) 1993 880207
Nominated Advisor and broker
Numis Securities Limited
10 Paternoster Row
020 7260 1000
PO Box 3043
Bond Dickinson LLP
St. Ann’s Warf
Newcastle upon Tyne
Tel: +44 (0) 844 984 1500
Fax: +44 (0) 844 984 1501
Neville Registrars Limited
18 Laurel Lane
Tel: +44 (0) 121 585 1131
Fax: +44 (0) 121 585 1132
Bank of Scotland
PO Box No 10
38 St. Andrews Square
Tel: +44 (0) 131 465 3900